In the phase-2 OPTIC (Optimizing Ponatinib Treatment in CML) trial, a PON dose reduction to 15 mg with a BCR-ABL1/ABL1 ratio < 1%IS was obtained [22]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.